{
    "eid": "2-s2.0-85140888545",
    "title": "Identification of Shared Neoantigens in BRCA1-Related Breast Cancer",
    "cover-date": "2022-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "BRCA1",
        "breast cancer",
        "cancer vaccine",
        "shared neoantigens"
    ],
    "authors": [
        "Lucksica Ruangapirom",
        "Nannapat Sutivijit",
        "Chinachote Teerapakpinyo",
        "Apiwat Mutirangura",
        "Chatchanan Doungkamchan"
    ],
    "citedby-count": 2,
    "ref-count": 47,
    "ref-list": [
        "Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy",
        "Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process",
        "Turning the corner on therapeutic cancer vaccines",
        "Advances in the development of personalized neoantigen-based therapeutic cancer vaccines",
        "Preclinical and clinical development of neoantigen vaccines",
        "Neoantigen vaccine: An emerging tumor immunotherapy",
        "Computational Prediction and Validation of Tumor-Associated Neoantigens",
        "Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities",
        "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries",
        "The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort",
        "BRCA1 and BRCA2 mutations across race and ethnicity: Distribution and clinical implications",
        "Landscape of somatic mutations in 560 breast cancer whole-genome sequences",
        "Signatures of mutational processes in human cancer",
        "Subtypes of familial breast tumours revealed by expression and copy number profiling",
        "Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)",
        "Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer",
        "TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes",
        "Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial",
        "Shared neoantigens: Ideal targets for off-the-shelf cancer immunotherapy",
        "Shared cancer neoantigens: Making private matters public",
        "A vaccine targeting mutant IDH1 induces antitumour immunity",
        "IDH1 and IDH2 mutations in gliomas",
        "Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets",
        "A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets",
        "Comprehensive Immune Profiling of Medullary Thyroid Cancer",
        "Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer",
        "Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors",
        "HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ",
        "Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion",
        "Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis",
        "A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma",
        "A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets",
        "Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology",
        "Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers",
        "Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants",
        "The Immune Epitope Database (IEDB): 2018 update",
        "NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data",
        "NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data",
        "Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes",
        "Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and new query tools",
        "Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer",
        "Frequency and spectrum of PIK3CA somatic mutations in breast cancer",
        "Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer",
        "The Function of the Mutant p53-R175H in Cancer",
        "Targeting a neoantigen derived from a common TP53 mutation",
        "Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations",
        "Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University"
    ]
}